Merck’s Biotech Pipeline Gets A Boost From Two Acquisitions
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck will buy the monoclonal antibody developer Abmaxis and yeast glycoengineering specialist GlycoFi.
You may also be interested in...
AbbVie Goes Boldly Into Immuno-Neurology With Alector
AbbVie agreed to pay $205m up front to biotech start-up Alector to research a portfolio of antibody targets to treat Alzheimer's and other neurodegenerative diseases by harnessing the immune system.
Merck Buys Contract Manufacturing Org Avecia To Advance Biologics Strategy
With the acquisition, Merck gains a contract manufacturing organization with specific expertise in microbial-derived biologics.
Merck Buys Contract Manufacturing Org Avecia To Advance Biologics Strategy
With the acquisition, Merck gains a contract manufacturing organization with specific expertise in microbial-derived biologics.